Iovance Biotherapeutics(IOVA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of$53-$55 Million for 3Q24,$160-$165 Million for FY24, and$450-$475 Million for FY25 SAN CARLOS, Calif., August 8, 2024 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delive ...